Literature DB >> 33320272

Chronic Nodular Prurigo: A European Cross-sectional Study of Patient Perspectives on Therapeutic Goals and Satisfaction.

Manuel P Pereira1, Claudia Zeidler, Joanna Wallengren, Jon Anders Halvorsen, Elke Weisshaar, Simone Garcovich, Laurent Misery, Emilie Brenaut, Ekin Şavk, Nikolay Potekaev, Andrey Lvov, Svetlana Bobko, Jacek C Szepietowski, Adam Reich, Agnieszka Bozek, Franz J Legat, Martin Metz, Markus Streit, Esther Serra-Baldrich, Margarida Gonçalo, Michael Storck, Teresa Nau, Vincent Hoffmann, Sabine Steinke, Ina Greiwe, Martin Dugas, Matthias Augustin, Sonja Ständer.   

Abstract

Chronic nodular prurigo is characterized by recalcitrant itch. Patient perspectives on therapeutic goals, satisfaction with therapy and efficacy of therapeutic regimens for this condition are unknown. This questionnaire study examined these issues in 406 patients with chronic nodular prurigo from 15 European dermatological centres. Improvements in itch, skin lesions and sleep were the most important goals. Emollients, topical corticosteroids and antihistamines were the most frequently used treatments, while a minority of patients were prescribed potent medications, such as systemic immunosuppressants and gabapentinoids. Most patients were not satisfied with their previous therapy (56.8%), while 9.8% did not receive any therapy despite having active disease. A substantial number of respondents (28.7%) considered none of the therapeutic options effective. Although chronic nodular prurigo is a severe disease, most patients were not treated with potent systemic drugs, which may contribute to the high levels of dissatisfaction and disbelief in available therapies. Specific guidelines for chronic nodular prurigo and the development of novel therapies are necessary to improve care.

Entities:  

Keywords:  chronic nodular prurigo; itch; patient-reported outcome; pruritus; therapy; nodular prurigo

Mesh:

Year:  2021        PMID: 33320272      PMCID: PMC9366694          DOI: 10.2340/00015555-3726

Source DB:  PubMed          Journal:  Acta Derm Venereol        ISSN: 0001-5555            Impact factor:   3.875


  31 in total

1.  European S2k Guideline on Chronic Pruritus.

Authors:  Elke Weisshaar; Jacek C Szepietowski; Florence J Dalgard; Simone Garcovich; Uwe Gieler; Ana M Giménez-Arnau; Julien Lambert; Tabi Leslie; Thomas Mettang; Laurent Misery; Ekin Şavk; Markus Streit; Erwin Tschachler; Joanna Wallengren; Sonja Ständer
Journal:  Acta Derm Venereol       Date:  2019-04-01       Impact factor: 4.437

2.  Chronic nodular prurigo: clinical profile and burden. A European cross-sectional study.

Authors:  M P Pereira; V Hoffmann; E Weisshaar; J Wallengren; J A Halvorsen; S Garcovich; L Misery; E Brenaut; E Savk; N Potekaev; A Lvov; S Bobko; J C Szepietowski; A Reich; A Bozek; F J Legat; M Metz; M Streit; E Serra-Baldrich; M Gonçalo; M Storck; I Greiwe; T Nau; S Steinke; M Dugas; S Ständer; C Zeidler
Journal:  J Eur Acad Dermatol Venereol       Date:  2020-05-12       Impact factor: 6.166

3.  Reduced Itch Associated With Dupilumab Treatment In 4 Patients With Prurigo Nodularis.

Authors:  Nicholas K Mollanazar; May Elgash; Leslie Weaver; Rodrigo Valdes-Rodriguez; Sylvia Hsu
Journal:  JAMA Dermatol       Date:  2019-01-01       Impact factor: 10.282

4.  Validation of Pruritus Measures Gathered with the Electronic Patient-reported Outcome System MoPat.

Authors:  Michael Storck; Claudia Zeidler; Mirjam Rehr; Claudia Riepe; Martin Dugas; Sonja Ständer; Iñaki Soto-Rey
Journal:  Acta Derm Venereol       Date:  2018-01-12       Impact factor: 4.437

5.  UVB 308-nm excimer light and bath PUVA: combination therapy is very effective in the treatment of prurigo nodularis.

Authors:  S Hammes; J Hermann; S Roos; H M Ockenfels
Journal:  J Eur Acad Dermatol Venereol       Date:  2010-10-15       Impact factor: 6.166

6.  [Antipruritic therapy with the oral opioid receptor antagonist naltrexone. Open, non-placebo controlled administration in 133 patients].

Authors:  A Brune; D Metze; T A Luger; S Ständer
Journal:  Hautarzt       Date:  2004-12       Impact factor: 0.751

7.  Antipruritic effect of cyclosporine microemulsion in prurigo nodularis: results of a case series.

Authors:  Dorothee Siepmann; Thomas A Luger; Sonja Ständer
Journal:  J Dtsch Dermatol Ges       Date:  2008-04-28       Impact factor: 5.584

8.  Treatment of prurigo with methotrexate: a multicentre retrospective study of 39 cases.

Authors:  T Klejtman; M Beylot-Barry; P Joly; M A Richard; S Debarbieux; L Misery; P Wolkenstein; O Chosidow; S Ingen-Housz-Oro
Journal:  J Eur Acad Dermatol Venereol       Date:  2017-11-07       Impact factor: 6.166

9.  Prurigo nodularis: retrospective study of 13 cases managed with methotrexate.

Authors:  P Spring; I Gschwind; M Gilliet
Journal:  Clin Exp Dermatol       Date:  2014-06       Impact factor: 3.470

10.  Prurigo nodularis: a physician survey to evaluate current perceptions of its classification, clinical experience and unmet need.

Authors:  M P Pereira; S Basta; J Moore; S Ständer
Journal:  J Eur Acad Dermatol Venereol       Date:  2018-07-01       Impact factor: 6.166

View more
  3 in total

Review 1.  Unmet Medical Needs in Chronic, Non-communicable Inflammatory Skin Diseases.

Authors:  Hideyuki Ujiie; David Rosmarin; Michael P Schön; Sonja Ständer; Katharina Boch; Martin Metz; Marcus Maurer; Diamant Thaci; Enno Schmidt; Connor Cole; Kyle T Amber; Dario Didona; Michael Hertl; Andreas Recke; Hanna Graßhoff; Alexander Hackel; Anja Schumann; Gabriela Riemekasten; Katja Bieber; Gant Sprow; Joshua Dan; Detlef Zillikens; Tanya Sezin; Angela M Christiano; Kerstin Wolk; Robert Sabat; Khalaf Kridin; Victoria P Werth; Ralf J Ludwig
Journal:  Front Med (Lausanne)       Date:  2022-06-09

Review 2.  Prurigo Nodularis: A Review of IL-31RA Blockade and Other Potential Treatments.

Authors:  Anthony Bewley; Bernard Homey; Andrew Pink
Journal:  Dermatol Ther (Heidelb)       Date:  2022-08-20

Review 3.  Pruritus: A Sensory Symptom Generated in Cutaneous Immuno-Neuronal Crosstalk.

Authors:  Attila Gábor Szöllősi; Attila Oláh; Erika Lisztes; Zoltán Griger; Balázs István Tóth
Journal:  Front Pharmacol       Date:  2022-03-07       Impact factor: 5.810

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.